加载中
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
前收盘价
US$26.40
−US$0.86 · -3.15%
盘后
US$26.40
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
日内区间
当前US$26.40
52周区间
当前US$26.40
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
52
合理估值
情绪
37
看跌
风险
52
风险偏高
动量
64
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
日内区间
当前US$26.40
52周区间
当前US$26.40
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 营收 | 1000万 USD | 500万 USD | 5000万 USD | — |
| 销货成本 | — | 1.39亿 USD | — | 6168.9万 USD |
| 毛利 | 1000万 USD | −1.34亿 USD | 5000万 USD | −6168.9万 USD |
| 研究与开发 | 1.68亿 USD | 1.39亿 USD | 6003.3万 USD | 6268.9万 USD |
| 销售、一般及管理费用 | 5332.2万 USD | 2974.9万 USD | 1711.4万 USD | 1351万 USD |
| 营业费用 | 2.21亿 USD | 2974.9万 USD | 8714.7万 USD | 1451万 USD |
| 利息收入 | 1215.1万 USD | — | — | — |
| 利息支出 | 732.7万 USD | — | — | — |
| 折旧和摊销 | 5.6万 USD | 13.7万 USD | 11.3万 USD | 7.8万 USD |
| 营业利润 | −2.11亿 USD | −1.64亿 USD | −3714.7万 USD | −7619.9万 USD |
| 净利润 | −3.78亿 USD | −1.57亿 USD | −3712.4万 USD | −1.19亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$43.50
上涨空间 64.77%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2880.35万0.00%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI2784.93万0.28%103.03亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM2561.11万0.03%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF1422.43万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO904.83万0.07%139.17亿 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB722.72万0.07%108.2亿 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA637.74万0.03%218.24亿 USD0.03%US$32.66-0.40%
Vanguard Russell 2000 ETFVTWO529.14万0.03%180亿 USD0.06%US$112.27-0.35%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
